Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term deferasirox treatment in beta-thalassemia with transfusional hemosiderosis
2016-004322-42Phase 4
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in Transfusional Siderosis and beta thalassemia, sponsored by Novartis. Primary endpoint: Treatment success from core baseline to extension end of study.
02
Drugs
deferasirox
03
Conditions
Transfusional Siderosisbeta thalassemia
Beyond the preview
Go deeper on 2016-004322-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004322-42.